Drug intelligence / Profile preview

sufentanil + ketamine

Development stage
Unknown
Lead developer
Cessatech
Modality
Small Molecules
Administration
Intravenous, Intranasal
01

Overview

Sufentanil + ketamine is a combination of two small molecule drugs used primarily for procedural sedation and analgesia, especially in perioperative or acute pain settings. Sufentanil is a potent synthetic opioid analgesic that acts as a selective agonist at the µ-opioid receptor, providing strong analgesia and sedation. Ketamine is a dissociative anesthetic that functions mainly as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, resulting in profound analgesia, amnesia, and maintenance of airway reflexes. When combined, these agents offer synergistic effects for pain control while potentially reducing the required doses of each drug and minimizing their respective side effects. This combination has been studied for use in patient-controlled intravenous analgesia (PCIA), procedural sedation (including intranasal administration), postoperative pain management, and emergency medicine[3][5][10]. The combination may reduce opioid requirements and lower the incidence of adverse events such as nausea or respiratory depression compared to higher doses of opioids alone.

Other names
sufentanil and ketaminesufentanil plus ketamine
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on sufentanil + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sufentanil + ketamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call